4 unknown, 2 active not recruiting, 2 recruiting, 1 completed. 11 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Unknown 4, Active not recruiting 2, Recruiting 2, Completed 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 3 | Recruiting 1, Unknown 1, Withdrawn 1 |
Follow HER-2 Protein Overexpression: new trials by email Literature Review of HER-2 Protein Overexpression trials Research Report on HER-2 Protein Overexpression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors Zanidatamab - Breast Cancer, Gastric Cancer | Phase 2 | Recruiting | Jazz Pharmaceuticals | 200 | 2025-01-14 | 2026-11-04 |
| Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer Disitamab vedotin, Bacillus Calmette Guerin Vaccine - Non-muscle Invasive Bladder Cancer, HER-2 Protein Overexpression | Phase 2 | Active not recruiting | Fudan University | 20 | 2023-12-18 | 2026-07-20 |
| DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With HER2 IHC2+/3+ ESCC RC48+PD-1+platinum-based - Esophageal Squamous Carcinoma, HER-2 Protein Overexpression | Phase 1 / Phase 2 | Unknown | Changhai Hospital | 20 | 2023-09-30 | 2023-09-26 |
| Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction Nivolumab, Trastuzumab deruxtecan - Esophageal Adenocarcinoma, Esophageal Cancer | Phase 2 | Active not recruiting | Brown University | 1 | 2023-07-14 | 2026-04-21 |
| PRE-ISPY Phase I/II Oncology Platform Program ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab - HER2-positive Breast Cancer, Metastatic Cancer | Phase 1 / Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | 280 | 2023-02-15 | 2026-09-30 |
| Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients Trastuzumab - Esophageal Squamous Cell Carcinoma, HER-2 Protein Overexpression | Phase 2 | Unknown | Morten Mau-Sørensen | 24 | 2022-02-04 | 2022-08-12 |
| Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers SNK01, Trastuzumab, Cetuximab - Advanced Solid Tumor, Metastatic Cancer | Phase 1 / Phase 2 | Withdrawn | NKGen Biotech, Inc. | 2021-03-01 | 2021-05-12 | |
| Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Solid Tumor Trastuzumab biosimilar, Gemcitabine Hydrochloride, Irinotecan Hydrochloride - HER-2 Protein Overexpression, HER-2 Gene Amplification | Phase 2 | Unknown | Jin-Hee Ahn | 42 | 2019-12-30 | 2020-01-02 |
| The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor Pyrotinib - Solid Tumor, HER2 Gene Mutation | Phase 2 | Unknown | Tianjin Medical University Second Hospital | 100 | 2019-12-01 | 2019-11-27 |
| Trastuzumab in HER2-positive Biliary Tract Cancer Trastuzumab - Cholangiocarcinoma, Biliary Tract Cancer | Phase 2 | Completed | Changhoon Yoo | 4 | 2019-06-01 | 2021-01-05 |
| Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1 HER2 DC1 Vaccine - Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 16 | 2019-01-10 | 2022-04-25 |
Breast Neoplasms (4) · Colorectal Neoplasms (3) · Esophageal Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Endometrial Neoplasms (2) · Neoplasm Metastasis (2) · Ovarian Neoplasms (2) · Pancreatic Neoplasms (2) · Stomach Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Adenocarcinoma (1) · Adenocarcinoma Of Esophagus (1) · Biliary Tract Neoplasms (1) · Breast Neoplasms, Male (1) · Carcinoma, Transitional Cell (1)
Neoplasms by Site (8) · Neoplasms (7) · Carcinoma (6) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms, Glandular and Epithelial (6) · Gastrointestinal Diseases (5) · Gastrointestinal Neoplasms (5) · Breast Diseases (4) · Esophageal Diseases (4) · Head and Neck Neoplasms (4) · Skin Diseases (4) · Skin and Connective Tissue Diseases (4) · Colonic Diseases (3)
Trastuzumab (3) · zanidatamab (2) · ALX148 (1) · BCG Vaccine (1) · Cetuximab (1) · Gemcitabine (1) · Irinotecan (1) · Nivolumab (1) · Vaccines (1) · disitamab vedotin (1) · pyrotinib (1) · trastuzumab deruxtecan (1) · tucatinib (1)
Brown University (1) · Changhai Hospital (1) · Changhoon Yoo (1) · Fudan University (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Jazz Pharmaceuticals (1) · Jin-Hee Ahn (1) · Morten Mau-Sørensen (1) · NKGen Biotech, Inc. (1) · QuantumLeap Healthcare Collaborative (1) · Tianjin Medical University Second Hospital (1)
United States (4) · China (2) · South Korea (2) · Denmark (1) · Georgia (1) · Spain (1)
Changhoon Yoo, MD (1) · Dingwei Ye (1) · Haitao Wang (1) · Howard Safran, MD (1) · Lene Baeksgaard, MD PhD (1) · Manish A Shah, MD (1) · Paul Y. Song, MD (1) · Paula R Pohlmann, MD, MSc, PhD (1) · Ricardo Costa, M.D. (1)